0.5802
Schlusskurs vom Vortag:
$0.598
Offen:
$0.595
24-Stunden-Volumen:
1.01M
Relative Volume:
1.15
Marktkapitalisierung:
$49.99M
Einnahmen:
$2.24M
Nettoeinkommen (Verlust:
$-136.67M
KGV:
-0.2534
EPS:
-2.29
Netto-Cashflow:
$-102.08M
1W Leistung:
-6.15%
1M Leistung:
-1.86%
6M Leistung:
-36.19%
1J Leistung:
-80.66%
Century Therapeutics Inc Stock (IPSC) Company Profile
Firmenname
Century Therapeutics Inc
Sektor
Branche
Telefon
215-981-4000
Adresse
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Vergleichen Sie IPSC mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IPSC
Century Therapeutics Inc
|
0.5802 | 53.26M | 2.24M | -136.67M | -102.08M | -2.29 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-08-08 | Eingeleitet | Rodman & Renshaw | Buy |
2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-12-27 | Eingeleitet | Chardan Capital Markets | Buy |
2022-10-31 | Eingeleitet | Guggenheim | Buy |
2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
2022-05-23 | Eingeleitet | H.C. Wainwright | Buy |
2022-05-12 | Eingeleitet | William Blair | Mkt Perform |
2021-07-13 | Eingeleitet | BofA Securities | Buy |
2021-07-13 | Eingeleitet | JP Morgan | Overweight |
2021-07-13 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Century Therapeutics Inc Aktie (IPSC) Neueste Nachrichten
University City biotech Century Therapeutics is cutting 72 jobs, about half its workforce - MSN
Why Century Therapeutics Inc. stock attracts strong analyst attentionMarket Trend Watch - Newser
Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com
Century Therapeutics to Present Preclinical Data at EULAR 2025 Congress - MSN
How Century Therapeutics Inc. stock performs during market volatilityFree Stock Market Query - Newser
What makes Century Therapeutics Inc. stock price move sharplyRisk Limited High Gain Trades - Newser
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock - Yahoo Finance
Layoff Tracker: Massachusetts-Based Karyopharm, Azurity Cut Workforces - BioSpace
Company’s Banking Stock: Dissecting a 51.83% Quarterly Revenue Decline Amid Growth - investchronicle.com
Century Therapeutics (NASDAQ:IPSC) Shares Down 0.9% – What’s Next? - Defense World
CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com
Century Therapeutics to reduce headcount by 51% - MarketScreener
Century Therapeutics Announces Major Workforce Reduction - TipRanks
Head-To-Head Contrast: Quince Therapeutics (NASDAQ:QNCX) and Century Therapeutics (NASDAQ:IPSC) - Defense World
Century Therapeutics Holds Annual Stockholder Meeting By Investing.com - Investing.com South Africa
Century Therapeutics Holds Annual Stockholder Meeting - Investing.com Australia
Century Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
66,797 Shares in Century Therapeutics, Inc. (NASDAQ:IPSC) Acquired by Two Sigma Investments LP - Defense World
Jane Street Group LLC Increases Stock Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics, Inc. (NASDAQ:IPSC) Shares Acquired by Squarepoint Ops LLC - Defense World
Two Sigma Advisers LP Takes $52,000 Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Nuveen Asset Management LLC Raises Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain - sharewise
Deutsche Bank AG Purchases 173,849 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Millennium Management LLC Grows Stock Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Q2 EPS Estimate for Century Therapeutics Raised by Analyst - Defense World
Brokers Issue Forecasts for IPSC Q1 Earnings - Defense World
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress - GlobeNewswire
Chardan Capital Issues Optimistic Forecast for IPSC Earnings - Defense World
Leerink Partnrs Has Negative Forecast for IPSC Q2 Earnings - Defense World
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Century Therapeutics Reports Strong Q1 2025 Earnings - TipRanks
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline - MSN
Chardan Trims Price Target on Century Therapeutics to $6 From $7, Maintains Buy Rating - marketscreener.com
Chardan Capital Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $6.00 - Defense World
Chardan Capital Lowers Price Target for Century Therapeutics (IP - GuruFocus
Chardan Capital Lowers Price Target for Century Therapeutics (IPSC) | IPSC Stock News - GuruFocus
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates - sharewise
Finanzdaten der Century Therapeutics Inc-Aktie (IPSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):